CTKBCytek Biosciences, Inc.
Price
+42%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growth fading, the market with it.
Charts
As reported to the SEC, without any scoring.
Cytek Biosciences, Inc. (CTKB) reported revenue of $48M in Q2 2026 (quarter ended Jun 30, 2026), up 5.6% from the same quarter a year earlier. That came with a gross margin of 59% and net loss of $12M. For the full year FY2025, revenue was $201M (+0.5% year on year) and net income −$67M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 23, 2026, the board of directors of Cytek Biosciences, Inc. (the “Company”) unanimously adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.Charter/bylaw amendment or fiscal-year change · Form 8-K
- Aug 24, 2026On August 21, 2026, the Company announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in the Company’s favor on three of the four asserted patent claims, finding noninfringement and …Regulation FD disclosure · Form 8-K
- Aug 5, 2026Cytek Biosciences Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.